SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Christian Atallah who wrote (665)5/1/1997 1:44:00 AM
From: George T. Santamaria   of 6136
 
AGPH has record losses this past FY with the commercialization of Viracept. Their losses have gone down in the recent quarter and they expect to be at breakeven in FY '98. At the present time, the sales momentum with Viracept is so strong that earnings forecasts will most likely increase, not decrease.

IBD appears to be on a different wavelength. This is a classic short sell pattern -- first, the slap on the wrist from the FDA, then the heavy short sell drop in stock price, a false slam from the media and, finally, a little rumor here and there. This should shake up a few unknowledgeable investors and a agitate a few short sellers with more money than sense.

I've been in this issue for 10+ years and it has never been stable and it has always had some gravity holding it back. This year and next will prove to be exciting.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News